CONCEPTUAL PAPERS & RESEARCH ON METHODSClinical Outcomes Methods
| PMC1 |
COLLECTING REAL DATA FROM REAL PATIENTS |
|
Wade AG, Crawford G |
|
Patients Direct, Glasgow, United Kingdom |
| |
|
| PMC2 |
HAS THE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME: AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS? |
|
Proudfoot CW1, Stoddart SD1, Muston D2 |
|
1Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom, 2Heron Evidence Development Ltd, Letchworth, United Kingdom |
| |
|
| PMC3 |
OVERCOMING THE FINAL HURDLE: COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG |
|
Shannon PR, Beard S |
|
RTI Health Solutions, Manchester, United Kingdom |
| CONCEPTUAL PAPERS & RESEARCH ON METHODSCost Methods |
| PMC4 |
FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY |
|
Calgan Z1, Ozer A2 |
|
1Hacettepe University, Ankara, Turkey, 2Social Security Institution, Ankara, Turkey |
| |
|
| PMC5 |
A MISSING DATA THRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA: DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS |
|
Bush S |
|
CRC/Cardiff Research Consortium, Cardiff, Glamorgan, United Kingdom |
| |
|
| PMC6 |
SOCIAL DISCOUNTING IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES |
|
Valentim J1, Prado Jr JM2 |
|
1University of São Paulo, São Paulo, SP, Brazil, 2IMT Lucca Institute for Advanced Studies, Lucca, Toscana, Italy |
| |
|
| PMC7 |
SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS |
|
Hoogendoorn M1, van Wetering CR2, Schols AM3, Rutten-van Mölken MP1 |
|
1Erasmus MC, Rotterdam, Netherlands, 2Maxima Medical Centre, Veldhoven, Netherlands, 3Maastricht University, Maastricht, Netherlands |
| |
|
| PMC8 |
DESIGN AND REPORTING TRENDS IN PIGGY-BACK ECONOMIC TRIALS |
|
Ubhadiya BS1, Gautam C1, Narvilkar P2, Singh N2, Bhanderi M2, Dimri S2 |
|
1Heron Health Pvt Ltd, Chandigarh, India, 2Heron Health Private Ltd, Chandigarh, India |
| |
|
| PMC9 |
DISCOUNTING COSTS AND BENEFITS OF HEALTH CARE PROGRAMMES: PROBLEMS OF THE SOCIAL TIME PREFERENCE APPROACH |
|
John J |
|
Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany |
| |
|
| PMC10 |
PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS |
|
Hoyle M, Anderson R |
|
University of Exeter, Exeter, England |
| |
|
| PMC11 |
IMPROVING PROBABILISTIC SENSITIVITY ANALYSIS (PSA) IN THE TREATMENT OF UNCERTAINTY COSTS USING MCMC |
|
Monleon-Getino A1,
Crespo C2, Rodriguez JM3, Ocaña J1 |
|
1University of Barcelona, Barcelona, Spain, 2Oblikue Consulting, Barcelona, Spain, 3Medtronic Iberia, Madrid, Spain |
| |
|
| PMC12 |
MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE: A STOCHASTIC APPLICATION IN DIABETES CARE |
|
Hoomans T1, Abrams K2, Evers SMAA1, Ament AJHA1, Severens JL3 |
|
1Maastricht University, Maastricht, Netherlands, 2University of Leicester, Leicester, United Kingdom, 3University Hospital Maastricht, Maastricht, Netherlands |
| |
|
| PMC13 |
ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS: AN ALTERNATIVE TO THE SMEARING APPROACH |
|
Exuzides A1, Colby C1, Spalding JR2 |
|
1ICON Clinical Research, San Francisco, CA, USA, 2Astellas Pharma US, Deerfield, IL, USA |
| |
|
| PMC14 |
A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS |
|
Grutters JP1, Joore MA2 |
|
1Maastro Clinic, Maastricht, Netherlands, 2University Hospital Maastricht, Maastricht, Netherlands |
| |
|
| PMC15 |
IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS |
|
Tilling CJ1,
Krol M2, Tsuchiya A3, Brazier JE3, Brouwer W2 |
|
1Sheffield University, Sheffield, United Kingdom, 2The institute for Medical Technology Assessment, Rotterdam, Netherlands, 3The University of Sheffield, Sheffield, South Yorkshire, United Kingdom |
| |
|
| PMC16 |
EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS |
|
Schlander M |
|
Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany |
| CONCEPTUAL PAPERS & RESEARCH ON METHODSDatabase Management Methods |
| PMC17 |
VALIDITY OF ELECTRONIC PRECRIPTION CLAIMS RECORDS: A COMPARISON OF ELECTRONIC PBM CLAIMS RECORDS WITH PHARMACY PROVIDER DERIVED RECORDS |
|
Martin BC1, Cox E2 |
|
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2Express Scripts Inc, Maryland Heights, MO, USA |
| CONCEPTUAL PAPERS & RESEARCH ON METHODSModeling Methods |
| PMC18 |
CONCEPTUALISING DISEASE: BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE STUDY IN ALZHEIMER'S DISEASE (AD) |
|
Wild D1, Nixon A1, Sculpher M2, Lloyd A1, Briggs A3, Mealing S1, Gallop K1 |
|
1Oxford Outcomes Ltd, Oxford, United Kingdom, 2University of York, York, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom |
| |
|
| PMC19 |
COST-EFFECTIVENESS ANALYSES OF BEHAVIORAL INTERVENTIONS: TOWARDS A MORE REALISTIC COST-EFFECTIVENESS RATIO BY INCLUDING INTERMEDIATE OUTCOME MEASURES |
|
Prenger R1, Braakman-Jansen LM1, Pieterse ME1, van der Palen J2, Seydel ER1 |
|
1University of Twente, Enschede, Netherlands, 2Medisch Spectrum Twente Hospital, Enschede, Netherlands |
| |
|
| PMC20 |
QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS |
|
Bolle M1,
Mukku SR2, Sparrowhawk K2, Tutt S2 |
|
1University of Cambridge, Cambridge, United Kingdom, 2PriceSpective, London, United Kingdom |
| |
|
| PMC21 |
ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE |
|
Gordon JP1, Bergenheim K2, Yuan Y3, Tetlow AP1, McEwan P1 |
|
1Cardiff Research Consortium, Cardiff, United Kingdom, 2AstraZeneca, Mölndal, Sweden, 3Bristol-Myers Squibb, Princeton, NJ, USA |
| CONCEPTUAL PAPERS & RESEARCH ON METHODSPatient-Reported Outcomes Studies |
| PMC22 |
THE IMPACT OF COMORBIDITY BURDEN AND AGE ON PREFERENCE-BASED HRQL IN THE UNITED STATES |
|
Sullivan PW, Ghushchyan VH |
|
University of Colorado Denver, Aurora, CO, USA |
| |
|
| PMC24 |
SELF-ASSESSED HEALTH STATUS IN POLAND: EQ-5D FINDINGS FROM POLISH VALUATION STUDY |
|
Golicki D1, Niewada M2, Jakubczyk M1, Wrona W1, Dwojak A3, Gasiewska A3, Holownia M3, Koltowski L3, Macioch T1, Hermanowski T1 |
|
1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, 3Medical University of Warsaw, Warsaw, Poland |
| |
|
| PMC25 |
WITHDRAWN |
|
|
|
|
| |
|
| PMC26 |
PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36 |
|
Chen T1, Li L2 |
|
1Zhejiang University, Hangzhou, China, 2Zhejiang University, Hangzhou, Zhejiang, China |
| |
|
| PMC27 |
DO LIKERT-TYPE SCALE AND VISUAL ANLOGUE SCALE MEASURE THE SAME QUALITY OF LIFE? |
|
Hsiao YY1,
Yao G2 |
|
1National Taiwan University, Taipei, Taiwan, Taiwan, 2National Taiwan University, Taipei, Taiwan |
| |
|
| PMC28 |
WITHDRAWN |
|
|
|
|
| |
|
| PMC29 |
PATIENT REPORTED OUTCOMES RESEARCH IN A REAL TIME PRACTICE NETWORK |
|
Barr JT1, Schumacher GE1, Myers E2, Snetselaar L3 |
|
1Northeastern University, Boston, MA, USA, 2American Dietetic Association, Chicago, IL, USA, 3University of Iowa, Iowa, IA, USA |
| |
|
| PMC30 |
THE IMPACT OF INITIAL DISEASE SEVERITY: AN APPLICATION TO EXISTING HEALTH ECONOMICS MODELS |
|
Taylor MJ, Whitehead S, Stelemekas M |
|
University of York, York, United Kingdom |
| |
|
| PMC31 |
VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION |
|
Golicki D1, Jakubczyk M1, Niewada M1, Wrona W1, Busschbach JJ2, Jablonska A1, Jawoszek A1, Mozenska O1, Kaminski B3, Hermanowski T1 |
|
1Medical University of Warsaw, Warsaw, Poland, 2Erasmus Medical Center, Rotterdam, Netherlands, 3Warsaw School of Economics, Warsaw, Poland |
| |
|
| PMC32 |
METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES: BEST PRACTICE GUIDELINES FOR DECISION-MAKING AND TRANSLATION OR ADAPTATION |
|
Eremenco S1, Houchin C2, Gawlicki M3, Chong LY4 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Oxford Outcomes Ltd, Oxford, Oxon, United Kingdom, 3Corporate Translations, Inc, East Hartford, CT, USA, 4NCC-AC, Royal College of Surgeons, London, United Kingdom |
| |
|
| PMC33 |
THE ROLE OF RANKING DATA IN HEALTH VALUATION |
|
Chuang LH, Kind P, Zarate V, Weatherly H |
|
University of York, York, United Kingdom |
| |
|
| PMC34 |
METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES RESEARCH |
|
Nixon A, Wild D |
|
Oxford Outcomes Ltd, Oxford, United Kingdom |
| |
|
| PMC35 |
WITHDRAWN |
|
|
|
|
| |
|
| PMC36 |
AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION - THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS THROUGH STRUCTURAL EQUATION MODELLING |
|
Chuang LH, Kind P |
|
University of York, York, United Kingdom |
| |
|
| PMC37 |
CHALLENGES OF TRANSLATING AND LINGUISTICALLY VALIDATING PRO MEASURES INTO SLAVIC LANGUAGES |
|
Merry R, Houchin C, Wild D |
|
Oxford Outcomes Ltd, Oxford, United Kingdom |
| |
|
| PMC38 |
INFLUENCE OF DEMOGRAPHIC AND CULTURAL PREDICTORS ON EQ-5D VALUE SET IN THE POLISH POPULATION |
|
Wrona W, Golicki D, Jakubczyk M, Niewada M, Orłowski K, Gaczkowska A, Zawodnik S |
|
Medical University of Warsaw, Warsaw, Poland |
| |
|
| PMC39 |
WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES |
|
Marant C1, Longin J2, Spizak C1, Patrick DL3, Saussier C2,
Arnould B1, Van Ganse E4 |
|
1Mapi Values France, Lyon, France, 2MAPI, Lyon, France, 3University of Washington, Seattle, WA, USA, 4Neuroepidemiology and Pharmacoepidemiology unit, Bron, France |
| |
|
| PMC40 |
STABILITY OF TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) STRUCTURE IN DIFFERENT PATHOLOGY SAMPLES |
|
Ruíz MÁ1,
Rejas J2, Pardo A1, Soto J2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain |
| |
|
| PMC41 |
METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES |
|
Salas M1, Zuluaga A1, Hughes D2, Cowell W3,
Lebmeier M4, Vardeva K5, Pisu M1, Shinogle J6 |
|
1University of Alabama at Birmingham, Birmingham, AL, USA, 2University of Bangor, Bangor, United Kingdom, 3Roche, Welwyn Garden City, United Kingdom, 4University of Sheffield, Sheffield, -, United Kingdom, 5Bristol-Myers Squibb, Uxbridge, United Kingdom, 6RTI International, Washington, DC, USA |
| |
|
| PMC42 |
PATIENT AND POPULATION HEALTH-STATE VALUES ARE COMPARABLE WHEN DERIVED BY ELEMENTARY MEASUREMENT METHODS |
|
Krabbe P1, Tromp N2, Ruers T3, Van Riel P1 |
|
1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 3Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands |
| |
|
| PMC43 |
USE OF AND COMPLIANCE WITH ELECTRONIC PATIENT REPORTED OUTCOMES WITHIN CLINICAL DRUG TRIALS |
|
Wenzel KW1, O'Gorman H2 |
|
1ClinPhone, Bradenton, FL, USA, 2ClinPhone, Nottingham, United Kingdom |
| |
|
| PMC44 |
THE SIGNIFICANCE OF PATIENT-REPORTED OUTCOMES TO FACILITATE MARKET ACCESS DURING A PRODUCT LIFECYCLE |
|
Rofail D1, Abetz L1, Heelis R1, Brown C2 |
|
1Mapi Values, Bollington, United Kingdom, 2Mapi Values France, Lyon, France |
| |
|
| PMC45 |
WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR? |
|
Proudfoot CW, Alnwick K |
|
Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom |
| |
|
| PMC46 |
SHOULD WE BE CONSIDERING COMPONENTS OF SOCIAL COGNITION MODELS TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSION MEDICATION? |
|
Reaney MD1, Martin C2, Speight J1 |
|
1AHP Research, Uxbridge, United Kingdom, 2University of the West of Scotland, Ayr, United Kingdom |
| |
|
| PMC47 |
A STUDY OF THE KEY FACTORS INFLUENCING THE PATIENT SATISFACTION IN INPATIENT AND OUTPATIENT SETTINGS |
|
Tsai SF, Yeh GC |
|
Taipei Medical University Hospital, Taipei, Taiwan |
| |
|
| PMC48 |
UPDATE OF TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA |
|
Caron M1, Emery MP1, Marquis P2, Piault E2 |
|
1Mapi Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA |
| |
|
| PMC49 |
COMPARISON OF HEALTH LOCUS OF CONTROL BETWEEN PHYSICIANS AND THE GENERAL PUBLIC: MULTI-GROUP STRUCTURAL EQUATION MODELING |
|
Tokuda Y1, Ohde S2, Takahashi O3, Omata F1, Jacobs J1, Hinohara S2, Fukui T3 |
|
1St. Luke's Life Science Institute, Chuo City, Tokyo, Japan, 2St. Luke's Life Science Institute, Chuo, Tokyo, Japan, 3St. Luke's International Hospital, Chuo, Tokyo, Japan |
| |
|
| PMC50 |
THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS |
|
Houchin C1, Nixon A1, Herdman M2, Juárez DM3, Labuschagne LA4, Manuel C5, Manuel F5, Wan Mahmud WMR6 |
|
1Oxford Outcomes Ltd, Oxford, Oxon, United Kingdom, 2Insight Consulting & Research, Mataró, Spain, 3Independent consultant, Mexico city, Mexico, 4Leona Labuschagne & Associates, Port Elizabeth, South Africa, 5Independent consultant, Chennai, India, 6Kedah Medical Centre, Kedah, Malaysia |
| |
|
| PMC51 |
UTILITIES OF THE EQ-5D: TRANSFERABLE OR NOT? INFLUENCE OF THE NATIONAL VALUE SETS OF THE EQ-5D ON THE INCREMENTAL UTILITIES OF TWO HEALTH STATES |
|
Knies S1, Evers SMAA1, Severens JL2, Candel MJJM1, Ament AJHA1 |
|
1Maastricht University, Maastricht, Netherlands, 2University Hospital Maastricht, Maastricht, Netherlands |
CONCEPTUAL PAPERS & RESEARCH ON METHODS
Study Design |
| PMC52 |
LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH) |
|
McKown S1,
Handa ML1, Gawlicki M2, Stankey C1 |
|
1Corporate Translations, Inc, Chicago, IL, USA, 2Corporate Translations, Inc, East Hartford, CT, USA |
| |
|
| PMC53 |
WITHDRAWN |
|
|
|
|
| |
|
| PMC54 |
THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES – DO WE NEED AN INDUSTRY STANDARD METHODOLOGY? |
|
Reaney MD, Howarth A, Khagram L, Speight J |
|
AHP Research, Uxbridge, Middlesex, United Kingdom |
| |
|
| PMC55 |
THE C-STATISTIC AND THE EFFICIENCY OF THE PROPENSITY SCORES MODEL: EVIDENCE FROM SIMULATED DATA |
|
Kiri VA1, Feudjo-Tepie M2 |
|
1PAREXEL International, London, United Kingdom, 2GlaxoSmithKline R&D, London, United Kingdom |
| |
|
| PMC56 |
THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE |
|
Knies S1, Ament AJHA1, Evers SMAA1, Severens JL2 |
|
1Maastricht University, Maastricht, Netherlands, 2University Hospital Maastricht, Maastricht, Netherlands |
| |
|
| PMC57 |
DISCONTINUOUS COST MEASUREMENT: HOW TO FILL IN THE GAPS? |
|
Hendriks MRC1, Evers SMAA2, Bleijlevens MHC2, van Haastregt JCM2, Crebolder HFJM2, van Eijk JTM2 |
|
1University Hospital Maastricht, Maastricht, Netherlands, 2Maastricht University, Maastricht, Netherlands |
| |
|
| PMC58 |
THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS: EVIDENCE FROM SIMULATED DATA |
|
Kiri VA1, Feudjo-Tepie M2 |
|
1PAREXEL International, London, United Kingdom, 2GlaxoSmithKline R&D, London, United Kingdom |
| |
|
| PMC59 |
WITHDRAWN |
|
|
|
|
| |
|
| PMC60 |
CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES |
|
Eckermann S1, Coory M2, Willan AR3 |
|
1Flinders University, Adelaide, South Australia, Australia, 2University of Queensland, Brisbane, Queensland, Australia, 3SickKids Research Insitute, Toronto, ON, Canada |
| |
|
| PMC61 |
THE IMPLICIT VALUE OF STATISTICAL LIFE: ESTIMATES DERIVED FROM PUBLIC INTERVENTIONS IMPLEMENTED IN THE NETHERLANDS |
|
Goebbels AFG1, Ament AJHA1, Novák A2, Veraart CPWM3, Severens JL4 |
|
1Maastricht University, Maastricht, Netherlands, 2Anovák-Services, Apeldoorn, Netherlands, 3Roche Nederland BV, Woerden, Netherlands, 4University Hospital Maastricht, Maastricht, Netherlands |
| |
|
| PMC62 |
UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN |
|
Herzberg T, Arnold B |
|
Evanston Northwestern Healthcare, Evanston, IL, USA |
| |
|
| PMC63 |
SYSTEMATIC REVIEW RELIABILITY: SENSITIVITY AND SPECIFICITY OF ONE VS. TWO REVIEWS |
|
Muston D, Alnwick K |
|
Heron Evidence Development Ltd, Letchworth, Hertfordshire, United Kingdom |
|
|
MENTAL HEALTHClinical Outcomes Studies
| PMH1 |
PREVALENCE OF TIC DISORDERS AND COEXISTENCE WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN A GERMAN COMMUNITY SAMPLE |
|
Schlander M1, Schwarz O1, Viapiano M2, Bonauer N2, Rothenberger A3, Roessner V3 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany, 3University of Göttingen, Göttingen, Germany |
| |
|
| PMH2 |
DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER: A STATISTICAL MEDIATION MODEL ANALYSIS |
|
Bollu V1, Cappelleri J2, Bushmakin AG3, Mychaskiw M4, Feltner D1 |
|
1Pfizer Global Research and Development, New London, CT, USA, 2Pfizer Inc, Groton, CT, USA, 3Pfizer, Inc, Groton, CT, USA, 4Pfizer Inc, New York, NY, USA |
| |
|
| PMH3 |
RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA |
|
Lyubov E1, Dzhatdoeva A2, Zhao Z3, Cain J4 |
|
1Moscow Institute of Psychiatry, Moscow, Russia, 2Janssen-Cilag Russia, Moscow, Russia, 3J&J Worldwide Health Economics & Pricing, Raritan, NJ, USA, 4Janssen Pharmaceutica, Beerse, Belgium |
| |
|
| PMH4 |
EFFICACY AND SAFETY OF ORAL ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE |
|
Jones MP1,
Nicholl D2, Trakas K3 |
|
1Macquarie University, North Ryde, Australia, 2Johnson & Johnson, Raritan, NJ, USA, 3Johnson & Johnson, Toronto, ON, Canada |
| |
|
| PMH5 |
COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION |
|
Kreilick C1, Seal B2, Tangirala M3 |
|
1PRO Unlimited, Bridgewater, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Smith Hanley Consulting Group LLC, Lake Mary, FL, USA |
| |
|
| PMH6 |
A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE |
|
Fajutrao L1, Locklear JC2, Priaulx J3, Heyes A4 |
|
1AstraZeneca R&D, Sodertalje, Sweden, 23AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3Mapi Values, Macclesfield, United Kingdom, 4Mapi Values Ltd, Cheshire, United Kingdom |
| |
|
| PMH7 |
PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY |
|
Mehnert A1, Hargarter L1, Diels J2 |
|
1Janssen-Cilag GmbH, Neuss, NRW, Germany, 2Johnson & Johnson Pharmaceutical Services, Beerse, Belgium |
| |
|
| PMH8 |
TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER: AN ADJUSTED INDIRECT COMPARISON |
|
Edwards SJ, Korim F |
|
AstraZeneca UK Ltd, Luton, United Kingdom |
| |
|
| PMH9 |
TOLERABILITY OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS |
|
Edwards SJ1, Smith CJ2 |
|
1AstraZeneca UK Ltd, Luton, United Kingdom, 2Guy's Hospital and Maudsley Hospital, London, United Kingdom |
| |
|
| PMH10 |
TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS IN SCHIZOPHRENIA |
|
Edwards SJ, Korim F |
|
AstraZeneca UK Ltd, Luton, United Kingdom |
| MENTAL HEALTHCost Studies |
| PMH11 |
DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE: THE BUDGET IMPACT OF ILLEGAL DRUGS |
|
Prieto L |
|
European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal |
| |
|
| PMH12 |
BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION - A DATABASE ANALYSIS IN GERMANY |
|
Rudolph I, Sindern J |
|
Janssen-Cilag GmbH, Neuss, Germany |
| |
|
| PMH13 |
COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND |
|
Walczak J, Dardzinski W, Pawlik D, Nogas G |
|
Arcana Institute, Cracow, Poland |
| |
|
| PMH14 |
THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA |
|
Meier G |
|
AstraZeneca, Luton, Bedfordshire, United Kingdom |
| |
|
| PMH15 |
COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER |
|
Fajutrao L1, Locklear JC2, Liu S3, Paulson OB4 |
|
1AstraZeneca R&D, Sodertalje, Sweden, 23AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 4AstraZeneca Pharmaceuticals, Södertälje, Sweden |
| |
|
| PMH16 |
THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY |
|
Kanbur B1, Karamustafalioglu O2, Dilbaz N3, Turkcan S4, Sarioz F1, Tatar F1 |
|
1Janssen-Cilag, Istanbul, Turkey, 2Sisli Etfal Training and Research Hospital, Istanbul, Turkey, 3Ankara Numune Training and Research Hospital, Ankara, Turkey, 4Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey |
| |
|
| PMH17 |
TREATMENT OF OPIATE DEPENDENT PATIENTS IN WALES WITH BUPRENORPHINE/NALOXONE - A COST-EFFECTIVENESS EVALUATION |
|
Gibbons CJ |
|
Schering-Plough, Welwyn Garden City, United Kingdom |
| |
|
| PMH18 |
THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY |
|
Sarioz F1, Dilbaz N2, Karamustafalioglu O3, Turkcan S4, Kanbur B1, Tatar F1 |
|
1Janssen-Cilag, Istanbul, Turkey, 2Ankara Numune Training and Research Hospital, Ankara, Turkey, 3Sisli Etfal Training and Research Hospital, Istanbul, Turkey, 4Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey |
| |
|
| PMH19 |
PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY |
|
Mæhlum E1,
Hansen K2, Sapin C2 |
|
1Lundbeck, Lysaker, Norway, 2Lundbeck SAS, Paris, France |
| |
|
| PMH20 |
ECONOMIC EVALUATION OF PALIPERIDONE ER FOR THE TREATMENT OF SCHIZOPHRENIA IN THE CONTEXT OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM |
|
Araujo D1,
Souza CPR2, Passos RBF3, Pereira M4 |
|
1State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2MedInsight, Rio de Janeiro, Brazil, 3Medinsight, Rio de Janeiro, Brazil, 4Janssen Cilag, Sao Paulo, Brazil |
| |
|
| PMH21 |
COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA: 12 MONTH DATA FROM CZECH REPUBLIC |
|
Skoupá J1, Cerna V1, Dolezal T2 |
|
1Pharma Projects, Prague, Czech Republic, 2Charles University, Praha, Czech Republic |
| |
|
| PMH62 |
ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS FLUOXETINE TREATMENT ALONE |
|
Snedecor SJ1, Botteman MF1, Schaefer K2, Sarocco P2, Barry N2, Pickard AS3 |
|
1Pharmerit North America LLC, Bethesda, MD, USA, 2Sepracor Inc, Marlborough, MA, USA, 3College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA |
| |
|
| PMH22 |
IMPACT ON SCHIZOPHRENIA INPATIENT RESOURCE USE FOLLOWING SWITCH TO LONG-ACTING RISPERIDONE IN FINLAND |
|
Seppälä N1, Hakala M2, Willis M3, Asseburg C3, Svensson M3, Persson U3,
Löthgren M4 |
|
1Harjavalta Hospital, Harjavalta, Finland, 2Janssen-Cilag Nordic, Espoo, Finland, 3IHE - The Swedish Institute for Health Economics, Lund, Sweden, 4Janssen-Cilag AB, Sollentuna, Sweden |
| |
|
| PMH23 |
THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR – THE ECONOMIC VALUE OF A NEW DRUG FORMULATION |
|
Laine J1, Järbrink K2 |
|
1AstraZeneca, Espoo, Finland, 2AstraZeneca, Mölndal, Sweden |
| |
|
| PMH24 |
DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION |
|
Camacho F1, Joish VN2, Drake C3,
Asche CV4 |
|
1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Henry Ford Hospital Sleep Center, Detroit, MI, USA, 4University of Utah College of Pharmacy, Salt Lake City, UT, USA |
| |
|
| PMH25 |
DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ELDERLY DEPRESSED MANAGED CARE POPULATION |
|
Camacho F1, Joish VN2, Drake C3,
Asche CV4 |
|
1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Henry Ford Hospital Sleep Center, Detroit, MI, USA, 4University of Utah College of Pharmacy, Salt Lake City, UT, USA |
| |
|
| PMH26 |
ONE YEAR PROSPECTIVE HEALTH CARE AND NON-HEALTHCARE RESOURCES USE AND COST STUDY IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE: A SPANISH PERSPECTIVE |
|
Coduras A1, Rabasa I1, Frank A2, Bermejo F3, López-Pousa S4, López Arrieta J1, Del Llano J1, León T5,
Rejas J6 |
|
1Gaspar Casal Foundation, Madrid, Spain, 2University Hospital La Paz, Madrid, Spain, 3University Hospital 12 de Octubre, Madrid, Spain, 4Hospital Santa Caterina, Girona, Spain, 5Pfizer Global Pharmaceuticals, New York, NY, USA, 6Pfizer Spain, Madrid, Spain |
| |
|
| PMH27 |
HEALTH SERVICE EXPENDITURES FOR PATIENTS WITH A DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY – AN AGE AND GENDER SPECIFIC ANALYSIS |
|
Schlander M1, Schwarz O1, Trott GE2, Viapiano M3, Bonauer N3 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University of Wuerzburg, Aschaffenburg, Germany, 3Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany |
| |
|
| PMH28 |
THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT |
|
Bergman A, Hjalte F, Persson U |
|
The Swedish Institute for Health Economics, IHE, Lund, Sweden |
| |
|
| PMH29 |
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES |
|
Birnbaum HG1, Kessler R2,
Joish VN3, Kelley D1, Hsieh M1, Ben-Hamadi R1, Greenberg P1 |
|
1Analysis Group, Inc, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA |
| |
|
| PMH30 |
ANTIDEPRESSANT THERAPY DURING PREGNANCY: AN INSIGHT ON ITS POTENTIAL HEALTH CARE COSTS |
|
Ramos E, Bérard A |
|
University of Montreal, Montreal, QC, Canada |
| |
|
| PMH31 |
A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE |
|
Wade AG1, Milea D2, Despiégel N2, Guelfucci F3, Toumi M4 |
|
1CPS Research, Glasgow, United Kingdom, 2Lundbeck SAS, Paris, France, 3Altipharm, Paris, France, 4Université Lyon I, Villeurbanne, France |
| |
|
| PMH32 |
A GPRD STUDY OF HEALTH CARE COST ASSOCIATED WITH DIFFERENT FIRST-LINE ANTIDEPRESSANT TREATMENTS IN SEVERE DEPRESSION |
|
Wade AG1, Saragoussi D2, Despiégel N2, Guelfucci F3, François C2 |
|
1CPS Research, Glasgow, United Kingdom, 2Lundbeck SAS, Paris, France, 3Altipharm, Paris, France |
| |
|
| PMH33 |
COST-UTILITY ANALYSIS OF DULOXETINE VERSUS VENLAFAXINE IN THE MANAGEMENT OF MAJOR DEPRESSION IN PORTUGAL |
|
Pinto CG1, Barbosa A2,
Miguel LS3, Feio M2 |
|
1Technical University of Lisbon, Lisboa, Portugal, 2Hospital de Santa Maria, Lisbon, Portugal, 3Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal |
| |
|
| PMH34 |
WORKPLACE BURDEN OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES |
|
Birnbaum HG1, Kessler R2,
Seal B3, Kelley D1, Hsieh M1, Ben-Hamadi R1, Greenberg P1 |
|
1Analysis Group, Inc, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA |
| |
|
| PMH35 |
COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980-2004. |
|
Saz-Parkinson Z, Cediel-García P, Rubio B, Amate JM, Medel-Herrero Á |
|
Instituto de Salud Carlos III, Madrid, Spain |
| MENTAL HEALTHPatient-Reported Outcomes Studies |
| PMH36 |
WHAT DO PATIENTS WITH SCHIZOPHRENIA WANT OUT OF THEIR MEDICATION? IDENTIFYING PATIENT REPORTED “PROCESSES” IN MENTAL HEALTH |
|
Schmeding A1, Bridges JF2, Rudolph I1 |
|
1Janssen-Cilag GmbH, Neuss, Germany, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA |
| |
|
| PMH37 |
SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW: RESULTS OF A QUANTITATIVE PATIENT SURVEY |
|
Schmeding A1, Bormann L2, Klose N1, Ibach B1 |
|
1Janssen-Cilag GmbH, Neuss, Germany, 2GfK AG, Nürnberg, Germany |
| |
|
| PMH38 |
CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY |
|
Bridges JF, Kinter ET |
|
Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA |
| |
|
| PMH39 |
RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS' REPORTED OUTCOMES IN SCHIZOPHRENIA: THE CONTRIBUTION OF THE EQ-5D |
|
Scalone L1, Pirfo E2, Mencacci C3, Ferrannini L4, Berto P5, Sturkenboom MC6, Bernareggi M7, Giustra MG7, Mantovani LG8 |
|
1Centre of Pharmacoeconomics, Milan, Italy, 2Mental Health Department G. Maccacaro, Torino, NA, Italy, 3Mental Health Department, Milan, NA, Italy, 4Mental Health Department ASL 3, Genova, Italy, 5PBE consulting, Verona, Italy, 6Erasmus University Medical Center, Soest, Netherlands, 7Janssen-Cilag SpA, Cologno Monzese, Milan, NA, Italy, 8University of Naples, Federico II, Naples, Italy |
| |
|
| PMH40 |
PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY: RESULTS FROM ADORE STUDY IN FRANCE |
|
Le Heuzey MF1, Tcherny-Lessenot S2, Raimond C2 |
|
1Robert Debre Hospital, Paris, France, 2Lilly France, Suresnes, France |
| |
|
| PMH41 |
SAD BLUE DEPRESSED DAYS, HEALTH–RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONG WOMEN IN A UNIVERSITY COMMUNITY |
|
Bastardo YM |
|
Central University of Venezuela, Caracas, Venezuela |
| |
|
| PMH42 |
HEALTH-RELATED QUALITY OF LIFE OF MARRIED, WORKING WOMEN WITH CHILDREN (SUPERWOMAN SYNDROME) IN KOREA |
|
Kim S1, Park S2, Park H3 |
|
1Kyung Hee University, Seoul, South Korea, 2Kyung Hee University, Yongin, Gyeonggi-Do, South Korea, 3Pochon CHA University, Sungnam, Gyeonggi-Do, South Korea |
| |
|
| PMH43 |
THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND BIPOLAR PATIENTS |
|
Maurino J1,
Cordero L1, Montejo A2, Rebollo P3, Cuervo J3, Diez T1, Tafalla M1, Hernandez R1 |
|
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2Salamanca University, Salamanca, Spain, 3BAP Health Outcomes Research, Oviedo, Spain |
| |
|
| PMH44 |
LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE “DEPRESSION IN THE MEDICALLY ILL-18” |
|
Las Hayas C, Padierna JA, Quintana JM, Orive M, Vrotsou K, Madrazo A, Aristegui E, Silva M |
|
Hospital Galdakao-Usansolo, Galdakao, Spain |
| |
|
| PMH45 |
A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY |
|
Rudolph I1, Bridges JF2, Schmeding A1 |
|
1Janssen-Cilag GmbH, Neuss, Germany, 2Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA |
| |
|
| PMH46 |
PATIENT PREFERENCES IN ADHD - DISCRETE CHOICE EXPERIMENT |
|
Mühlbacher AC1, Rudolph I2, Lincke HJ1, Nübling M1 |
|
1Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany, 2Janssen Cilag GmbH, Neuss/Germany, D-41470 Neuss, Germany |
| |
|
| PMH47 |
QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA |
|
Wagner S, Kannan H, Bolge SC |
|
Consumer Health Sciences, Princeton, NJ, USA |
| |
|
| PMH48 |
TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER |
|
Ciesla JR |
|
Northern Illinois University, DeKalb, IL, USA |
| |
|
| PMH49 |
INTERNATIONAL INVESTIGATION INTO DEPRESSION BASED ON THE STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON DEPRESSION RATING SCALE (SIGH-D) AND THE CLINICIAN RATED INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (IDS-C) |
|
Caire P1, Bowers B2, Williams BW J3, Rush A J4 |
|
1Mapi Research Institute, Lyon, France, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3MedAvante, Inc, Hamilton, NJ, USA, 4University of Texas Southwestern Medical Center, Dallas, TX, USA |
| |
|
| PMH50 |
THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION |
|
Gerhards SAH, Goossens MEJB, Huibers MJH, de Graaf LE, Evers SMAA |
|
Maastricht University, Maastricht, Netherlands |
| MENTAL HEALTHHealth Care Use & Policy Studies |
| PMH51 |
DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANT WARNINGS |
|
Libby AM, Orton HD, Valuck RJ |
|
University of Colorado Denver, Aurora, CO, USA |
| |
|
| PMH52 |
PILOT SURVEY OF ADVERSE EVENT MANAGEMENT ASSOCIATED WITH ANTIPSYCHOTIC USE: THE NEGLECTED DIMENSION IN RESOURCE USE IMPLICATIONS (A UK PERSPECTIVE) |
|
Meier G, Malcolm B |
|
AstraZeneca, Luton, Bedfordshire, United Kingdom |
| |
|
| PMH53 |
PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN: A PROSPECTIVE COHORT STUDY BASELINE ASSESSMENT |
|
Tafalla M1, Vieta E2, de Dios C3, Goikolea J2, Saiz-Ruiz J4, González-Pinto A5, Montes JM6, Diez T1 |
|
1AstraZeneca, Madrid, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Centro de Salud Mental Fuencarral-El Pardo, Madrid, Spain, 4Hospital Ramón y Cajal, Madrid, Spain, 5Hospital de Santiago Apóstol, Vitoria, Spain, 6Hospital del Sureste, Arganda del Rey, Spain |
| |
|
| PMH54 |
INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION – A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND |
|
Gothe H1, Hagenmeyer EG1, Höer A1, Runge C2, Volmer T2, Häussler B1 |
|
1IGES Institut GmbH, Berlin, Germany, 2Wyeth Pharma GmbH, Münster, Germany |
| |
|
| PMH55 |
A COMPARISON OF PERSISTENCE AND HEALTH CARE COSTS RELATED TO DIFFERENT TREATMENT STRATEGIES AFTER INITIAL ESCITALOPRAM 10MG IN MAJOR DEPRESSIVE DISORDER |
|
Sanglier T1, Milea D2, Saragoussi D2, Toumi M1 |
|
1Université Lyon I, Villeurbanne, France, 2Lundbeck SAS, Paris, France |
| |
|
| PMH56 |
PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN: A NATIONWIDE STUDY, 2006 |
|
Chou LF1,
Chen TJ2 |
|
1National Chengchi University, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan |
| |
|
| PMH57 |
SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER: A CLAIMS DATA ANALYSIS |
|
Pikalov A1, Whitehead R1, Werner C2, Kim E3 |
|
1Otsuka America Pharmaceuticals Inc, Rockville, MD, USA, 2Otsuka Pharma GmbH, Frankfurt, Hessen, Germany, 3Bristol-Myers Squibb, Plainsboro, NJ, USA |
| |
|
| PMH58 |
BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE IN GERMANY: A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS |
|
Gaudig M |
|
Janssen-Cilag, Neuss, Germany |
| |
|
| PMH59 |
MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES |
|
Pechlivanoglou P, Boersma C, Visser ST, Postma MJ |
|
University of Groningen, Groningen, Netherlands |
| |
|
| PMH60 |
DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE: PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UNITED KINGDOM |
|
Saragoussi D1, Milea D1, Despiégel N1, Guelfucci F2, Toumi M3 |
|
1Lundbeck SAS, Paris, France, 2Altipharm, Paris, France, 3Université Lyon I, Villeurbanne, France |
| |
|
| PMH61 |
ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY - PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN PRACTICE |
|
Slawik L, Rudolph I |
|
Janssen Cilag GmbH, Neuss, Germany |
|
|
NEUROLOGICAL DISORDERSClinical Outcomes Studies
| PND1 |
INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING |
|
Zachry III WM1, Doan QD1, Smith BJ2, Clewell JD1, Griffith JM1 |
|
1Abbott Laboratories, Abbott Park, IL, USA, 2Henry Ford Hospital, Detroit, MI, USA |
| |
|
| PND2 |
HUNTINGTON'S DISEASE: WHERE HAVE WE BEEN? |
|
Samuels E, Stoddart SD, Lock K, Karia R |
|
Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom |
| |
|
| PND3 |
ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS) |
|
Mann TA, Rascati KL, Richards KM, Johnsrud M |
|
The University of Texas at Austin, Austin, TX, USA |
| NEUROLOGICAL DISORDERSCost Studies |
| PND4 |
GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS |
|
Castelli-Haley J1, Oleen-Burkey M1, Lage M2, Johnson K3 |
|
1Teva Neuroscience, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Groton, CT, USA, 3University of Maryland, Baltimore, MD, USA |
| |
|
| PND5 |
WITHDRAWN |
|
|
|
|
| |
|
| PND6 |
GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS |
|
Castelli-Haley J1, Oleen-Burkey M1, Lage M2, Johnson K3 |
|
1Teva Neuroscience, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Groton, CT, USA, 3University of Maryland, Baltimore, MD, USA |
| |
|
| PND7 |
COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN THE NETHERLANDS |
|
Nuijten MJ1, Pais BR2, Liedgens H3, van Wijck AJ4 |
|
1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, Netherlands, 2Grunenthal BV, Bunnik, Netherlands, 3Grünenthal GmbH, Aachen, Germany, 4University Utrecht - UMCU, Utrecht, Netherlands |
| |
|
| PND8 |
COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY |
|
Nuijten MJ1, Mittendorf T2, Jäcker A3, Osowski U4 |
|
1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, Netherlands, 2Leibniz University of Hannover, Hannover, Germany, 3Serono GmbH, Darmstadt, Germany, 4Merck Pharma GmbH, darmstadt, Germany |
| |
|
| PND9 |
WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE (STAR) |
|
King D1, Knapp M1, Kan HJ2, Pugner K3, van Baardewijk M3 |
|
1London School of Economics, London, United Kingdom, 2Bristol-Myers Squibb, Wallingford, CT, USA, 3Bristol-Myers Squibb, Braine-l'Alleud, Belgium |
| |
|
| PND10 |
BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY) |
|
Collar JM1, Porta-Etessam J2, Tobaruela JL3, Rabes C1, Casado MA4 |
|
1Grünenthal Group Spain, Madrid, Spain, 2Hospital Clinico San Carlos, Madrid, Spain, 3Hospital Virgen de la Poveda, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain |
| |
|
| PND11 |
EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED |
|
Birnbaum H1, Ivanova J2, Kidolezi Y1,
Caleo S3 |
|
1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, New York, NY, USA, 3Janssen Pharmaceutica N.V, Beerse, Belgium |
| |
|
| PND12 |
COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE |
|
Bénard S1, Pinchinat S2, Gallais JL3, Mick G4, Simon F5,
Beillat M6 |
|
1StèVe Consultants, Lyon, France, 2Biostatem, Castries, France, 3Société Française de Médecine Générale, Paris, France, 4Groupe d'Experts Douleurs Neuropathiques, Voiron, France, 5Instituto de Salud Carlos III, Madrid, Spain, 6sanofi pasteur MSD, Lyon, France |
| |
|
| PND13 |
ALZHEIMER'S DISEASE PRESCRIPTION MEDICATION COSTS: 2004-2005 |
|
Anderson K |
|
Uniformed Services University of the Health Sciences, Bethesda, MD, USA |
| |
|
| PND14 |
MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY |
|
Eidt D, Mittendorf T, von der Schulenburg JM |
|
Leibniz University of Hannover, Hannover, Germany |
| |
|
| PND15 |
THE INDIRECT COST BURDEN OF EPILEPSY IN THE UNITED STATES |
|
Birnbaum H1, Ivanova J2, Kidolezi Y1,
Caleo S3 |
|
1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, New York, NY, USA, 3Janssen Pharmaceutica N.V, Beerse, Belgium |
| |
|
| PND16 |
INDIRECT COSTS OF ALZHEIMER'S DISEASE IN THE UNITED STATES |
|
Anderson K |
|
Uniformed Services University of the Health Sciences, Bethesda, MD, USA |
| |
|
| PND17 |
ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO: RATIONAL OR NOT? |
|
Duborija-Kovacevic N1, Vujisic S2 |
|
1University of Montenegro Medical School, Podgorica, Serbia and Montenegro, 2Clinical Centre of Montenegro, Podgorica, Montenegro, Serbia and Montenegro |
| |
|
| PND18 |
RUFINAMIDE IN THE ADJUNCTIVE TREATMETN OF LENNOX-GASTAUT SYNDROME (LGS): A COST EFFECTIVENESS ANALYSIS |
|
Yi Y1,
Verdian L2, Jansen JP3 |
|
1Mapi Values, Cheshire, United Kingdom, 2Eisai Europe Limited, Hatfield, Herthfordshire, United Kingdom, 3Mapi Values, Houten, Netherlands |
| |
|
| PND19 |
NATALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS OF HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS |
|
O'Day K1, Meyer K1,
Rajagopalan K2 |
|
1Xcenda, Palm Harbor, FL, USA, 2Biogen Idec Pharmaceuticals, Cambridge, MA, USA |
| NEUROLOGICAL DISORDERSPatient-Reported Outcomes Studies |
| PND20 |
MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE: A SYSTEMATIC REVIEW |
|
Khagram L, Reaney MD |
|
AHP Research, Uxbridge, United Kingdom |
| |
|
| PND21 |
SYMPTOM SEVERITY IN PARKINSON'S DISEASE SCALE (SSPDS): A NEW PATIENT-REPORTED OUTCOME MEASURE OF PARKINSON'S DISEASE SEVERITY |
|
Schröder S, Schaefer M, Martus P |
|
Charité University Medicine, Berlin, Germany |
| |
|
| PND22 |
ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME |
|
Yi Y1,
Verdian L2, Oyee J3, Tolley K3, Heyes A4 |
|
1Mapi Values, Cheshire, United Kingdom, 2Eisai Europe Limited, Hatfield, United Kingdom, 3Mapi Values, Bollington, United Kingdom, 4Mapi Values Ltd, Bollington, United Kingdom |
| |
|
| PND23 |
RELATIONSHIP BETWEEN CHANGES IN EQ-5D DERIVED UTILITY SCORES AND CHANGES IN IRLS SUM SCORES FROM A MAPPING EXERCISE IN TWO PHASE III CLINICAL TRIALS |
|
Tan SC1, Brabant Y2, Grosset D3, Briggs A4 |
|
1UCB, Slough, Berkshire, United Kingdom, 2UCB S.A, Braine, Belgium, 3Institute of Neurological Sciences, Glasgow, United Kingdom, 4University of Glasgow, Glasgow, United Kingdom |
| |
|
| PND24 |
CAN THE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY? |
|
de La Loge C1, Yang H2, Schiemann J2, Hunter SJ3 |
|
1UCB Pharma SA, Braine l'Alleud, Belgium, 2UCB Inc, Smyrna, GA, USA, 3University of Chicago, Chicago, IL, USA |
| |
|
| PND25 |
EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSON'S DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING |
|
Andrés I1, Kulisevsky J2, Balañá M1, Pagonabarraga J2, Llebaria G2, Gobartt AL3, Arranz J4 |
|
1NOVARTIS FARMACEUTICA S.A, Barcelona, Spain, 2Hospital de Sant Pau, Barcelona, Spain, 3Novartis Pharmaceuticals, Barcelona, Spain, 4LABORATORIOS ESTEVE, Barcelona, Spain |
| |
|
| PND26 |
ARE THERE DIFFERENCES IN PATIENT SATISFACTION WITH INSOMNIA MEDICATIONS? PILOT RESULTS FROM A NOVEL REGISTRY |
|
Bharmal M1, Cascade EF2, Gemmen EK1 |
|
1Quintiles, Falls Church, VA, USA, 2iGuard Inc, Falls Church, VA, USA |
| NEUROLOGICAL DISORDERSHealth Care Use & Policy Studies |
| PND27 |
UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS : AN ITALIAN PRESCRIPTION DATABASE ANALYSIS |
|
Menditto E, De Portu S, Cammarota S, Citarella A, Riegler S, Mantovani LG |
|
University of Naples, Federico II, Naples, Italy |
| |
|
| PND28 |
TRENDS IN RESEARCH INTO CENTRAL NERVOUS SYSTEM DISORDERS: THE INFLUENCE OF AN AGING POPULATION |
|
Lock K, Samuels E |
|
Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom |
| |
|
| PND29 |
EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS: USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS |
|
Sicras-Mainar A1, Navarro-Artieda R2, Velasco-Velasco S1, Llopart-Lopez JR1, Rejas J3 |
|
1Badalona Serveis Assistencials SA, Barcelona, Spain, 2Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain, 3Pfizer Spain, Madrid, Spain |
| |
|
| PND30 |
NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH: AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT |
|
Bueno RLP, Pereira MF |
|
FEI, São Paulo, Brazil |
| |
|
| PND31 |
DESCRIPTIVE STUDY OF THE PHARMACOLOGICAL TREATMENTS USED IN PATIENTS WITH DEPRESSION IN PARKINSON'S DISEASE (PD) |
|
Sunderland TJ, Lee S, Das Gupta R |
|
Boehringer Ingelheim, Bracknell, United Kingdom |
| |
|
SENSORY SYSTEMS DISORDERSClinical Outcomes Studies
| PSS1 |
RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS |
|
Han C1, Zhao N2, Waters H2, Schenkel B1 |
|
1Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA |
| |
|
| PSS2 |
EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES |
|
Berdeaux G1, Feneron D2, Meunier J3, Viala-Danten M3, Arnould B3, Maurel F4 |
|
1Alcon France, Rueil-Malmaison, France, 2IMS Health, Puteaux, France, 3Mapi Values, Lyon, France, 4Aremis, Neuilly sur Seine, France |
| |
|
| PSS3 |
VISION WITH RESTOR® , ARRAY® SA40 AND A MONOFOCAL INTRA-OCULAR LENS (IOL) AFTER CATARACT SURGERY |
|
De vries N1, Lafuma A2, Laurendeau C3,
Berdeaux G4, Nuijts R1 |
|
1University Hospital Maastricht, Maastricht, Netherlands, 2Cemka eval, Bourg-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France, 4Alcon France, Rueil-Malmaison, France |
| |
|
| PSS4 |
RESTOR® VERSUS ACRILISA® ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY |
|
Gauthier L1, Lafuma A2, Laurendeau C2,
Berdeaux G3 |
|
1Polyclinique Côte Basque Sud, Saint jean de Luz, France, 2Cemka-Eval, Bourg-la-Reine, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
| PSS5 |
IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE (IOP) CONTROL IN GLAUCOMA PATIENTS |
|
Lafuma A1, Laurendeau C1, Jeanbat V1,
Berdeaux G2 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
| PSS6 |
EFFECTIVENESS OF MOXIFLOXACIN IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS IN ADULTS |
|
Lafuma A1, Koshnood B1, Laurendeau C1,
Berdeaux G2 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
| PSS7 |
A MIXED TREATMENT COMPARISON OF TOPICAL OCULAR HYPOTENSIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION |
|
Orme M1, Loftus J2,
Collins S1, Kelly S2 |
|
1Abacus International, Bicester, Oxfordshire, United Kingdom, 2Pfizer Ltd, Walton on the Hill, Surrey, United Kingdom |
| |
|
| PSS8 |
ATOPIC DERMATITIS IN CHILDHOOD: WHAT “DERMATOLOGICAL FUTURE” FOR THESE CHILDREN? |
|
Misery L1,
Boussetta S2, Taieb C2 |
|
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France |
| |
|
| PSS9 |
SENSITIVE SCALP: AN EPIDEMIOLOGICAL APPROACH |
|
Misery L1,
Boussetta S2, Taieb C2 |
|
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France |
| |
|
| PSS10 |
SENSITIVE SKIN IN EUROPE : AN EPIDEMIOLOGICAL APPROACH |
|
Misery L1,
Boussetta S2, Taieb C2 |
|
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France |
| |
|
| PSS11 |
SENSITIVE SKINS IN FRANCE: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS12 |
SENSITIVE SKINS IN PORTUGAL: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS13 |
HAIR LOSS: AN EPIDEMIOLOGICAL APPROACH |
|
Misery L1,
Boussetta S2, Taieb C2 |
|
1Hopital Morvan, Brest, France, 2Pierre Fabre, Boulogne, France |
| |
|
| PSS14 |
DRY SKIN: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S1, Taieb C2 |
|
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE, France |
| |
|
| PSS15 |
SENSITIVE SKINS IN SPAIN: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS16 |
SENSITIVE SKINS IN GERMANY: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS17 |
SENSITIVE SKINS IN BELGIUM: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS18 |
SENSITIVE SKINS IN SWITZERLAND: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS19 |
SENSITIVE SKINS IN GREECE: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS20 |
SENSITIVE SKINS IN ITALY: AN EPIDEMIOLOGICAL APPROACH |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS21 |
ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY |
|
Schlander M1, Schwarz O1, Viapiano M2, Bonauer N2 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany |
| |
|
| PSS22 |
FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN |
|
Arias A1, Schargel K2, Ussa F3, Canut MI4, Robles A4,
Martí B5 |
|
1Hospital de Alcorcón, Alcorcón, Madrid, Spain, 2Hospital de Torrevieja, Torrevieja, Alicante, Spain, 3Instituto Universitario de Oftalmobiología Aplicada, Valladolid, Spain, 4Centro de Oftalmología Barraquer, Barcelona, Spain, 5Universidad Autónoma de Madrid, Madrid, Spain |
| |
|
| PSS23 |
TOPICAL TACROLIMUS FOR THE TREATMENT OF ATOPIC DERMATITIS: A SYSTEMATIC REVIEW WITH META-ANALYSES |
|
Svensson Å1, Gånemo A1, Chambers C2, Mitchell S3 |
|
1University of Lund, Malmö, Sweden, 2Astellas Pharma Europe Ltd, Staines, United Kingdom, 3Abacus International, Bicester, United Kingdom |
| |
|
| PSS24 |
SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS REGARDING THE COMPARATIVE INCIDENCE OF HYPERAEMIA OF PROSTAGLANDIN TOPICAL GLAUCOMA MEDICATIONS |
|
Lee CW1, Stoddart SD2, Muston D2, Buckley F2, Costello S2, Kelly S1 |
|
1Pfizer, Tadworth, Surrey, United Kingdom, 2Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, United Kingdom |
| SENSORY SYSTEMS DISORDERSCost Studies |
| PSS25 |
COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS |
|
Ortonne JP1, Feneron D2, Daures JP3, Ollivier AL4, Thiriet C4,
Maurel F5, Le Pen C6 |
|
1Hopital Archet II, Nice, France, 2IMS health, Puteaux, France, 3CHU de Nimes, Nimes, France, 4Wyeth Pharmaceuticals, Paris La Defense, France, 5IMS Health, Puteaux, France, 6Dauphine University, Paris, France |
| |
|
| PSS26 |
PHARMACOECONOMIC EVALUATION OF RANIBIZUMAB IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN AUSTRIA |
|
Walter E1, Brennig C1, Moeremans K2, Thomas V3 |
|
1IPF - Institute for Pharmaeconomic Research, Vienna, Austria, 2IMS HEOR, Brussels, Belgium, 3Novartis Pharma AG, Basel, Switzerland |
| |
|
| PSS27 |
COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN THE NETHERLANDS: RESTOR®, ARRAY-SA40® AND A MONOFOCAL |
|
De vries N1, Lafuma A2, Laurendeau C2,
Berdeaux G3, Nuijts R1 |
|
1University Hospital Maastricht, Maastricht, Netherlands, 2Cemka-Eval, Bourg-la-Reine, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
| PSS28 |
VENOUS LEG ULCER. COSTS-OF-ILLNESS OF IN GERMANY. A NATIONAL CROSS-SECTIONAL STUDY |
|
Purwins S1, Augustin M1, Herberger K1, Debus S2, Rustenbach SJ1 |
|
1University Clinics of Hamburg, Hamburg, Germany, 2Asklepios Klinik Harburg, Hamburg, Germany |
| |
|
| PSS29 |
SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY |
|
Hieke K1, Diepgen T2 |
|
1NEOS Health, Binningen, Switzerland, 2University Hospital Heidelberg, Heidelberg, Germany |
| |
|
| PSS30 |
COST OF SPECTACLES AFTER CATARACT SURGERY IN THE NETHERLANDS |
|
De vries N1, Nuijts R1, Lafuma A2, Jeanbat V2, Laurendeau C2,
Berdeaux G3 |
|
1University Hospital Maastricht, Maastricht, Netherlands, 2Cemka-Eval, Bourg-la-Reine, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
| PSS31 |
ACUTE OTITIS MEDIA: A MAJOR SOURCE OF PRODUCTIVITY LOSS |
|
Stolk E1, Wolleswinkel-van den Bosch J2,
Laplante S3 |
|
1Erasmus Medical Center, Rotterdam, Netherlands, 2Pallas Health Research and Consultancy B.V, Rotterdam, Netherlands, 3GlaxoSmithKline Biologicals, Rixensart, Belgium |
| |
|
| PSS32 |
COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10 EUROPEAN COUNTRIES |
|
Hommer AB1, Wickstrom J2, Walt JG3,
Buchholz P4 |
|
1Krankenhaus Hera Vienna, Vienna, Austria, 2Muusmann Research & Consulting A/S, Kolding, Denmark, 3Allergan Inc, Irvine, CA, USA, 4Allergan Europe, Ettlingen, Germany |
| |
|
| PSS33 |
THE COST OF UVEITIS TREATMENT IN FRANCE: A ONE-YEAR RETROSPECTIVE ANALYSIS |
|
Kobelt G1, Bodaghi B2, Richard B1, Plesnilla C3, Buchholz P4, Brézin AP5, Heron E6, Labetoulle M7, Sahel J6 |
|
1European Health Economics, Speracedes, France, 2Pitié Salpêtrière, Paris, France, 3Medical Economics Research Group, Munich, Germany, 4Allergan Europe, Ettlingen, Germany, 5Hôpital Cochin-Université Paris 5, Paris, France, 6CHNO des XV-XX, Paris, France, 7CHU de Bicêtre, Le Kremlin-Bicêtre, France |
| |
|
| PSS34 |
MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION |
|
Orme M1, Loftus J2,
Collins S1 |
|
1Abacus International, Bicester, United Kingdom, 2Pfizer Ltd, Walton on the Hill, United Kingdom |
| |
|
| PSS35 |
COST UTILITY OF BILATERAL COCHLEAR IMPLANT |
|
Callejo D, López-Pedraza MJ, Llorente C, Maeso S, Martín C, Blasco JA |
|
Agencia Laín Entralgo, Madrid, Spain |
| |
|
| PSS36 |
THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UNITED KINGDOM |
|
Conway P1, Currie CJ2 |
|
1Wyeth Europa, Berkshire, United Kingdom, 2Cardiff University, Cardiff, United Kingdom |
| SENSORY SYSTEMS DISORDERSPatient-Reported Outcomes Studies |
| PSS37 |
IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA TREATMENT |
|
Regnault A1, Viala M1, Vigneux M2,
Berdeaux G3 |
|
1Mapi Values France, Lyon, France, 2Mapi Values, Lyon, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
| PSS38 |
RELATION BETWEEN SELF REPORTED GLAUCOMA SYMPTOMS AND COMPLIANCE |
|
Ruiz MA1, Pardo A1, Martínez de la Casa JM2, Polo V3, Esquirol J4, Soto J5 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Centro Médico Tecnón, Barcelona, Spain, 5Outcomes Research, Pfizer, Spain |
| |
|
| PSS39 |
QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN |
|
Puig L1, Sánchez-Carazo JL2, Daudén E3, Vanaclocha F4, Toribio J5, Pujol R6, Casado MA7,
Sabater FJ8 |
|
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital General de Valencia, Valencia, Spain, 3Hospital La Princesa, Madrid, Spain, 4Hospital 12 de Octubre, Madrid, Spain, 5Complejo Hospitalario de Santiago, Santiago de Compostela, Spain, 6Hospital del Mar, Barcelona, Spain, 7Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 8Schering-Plough S.A, Alcobendas, Spain |
| |
|
| PSS40 |
RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOW VISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY |
|
Shimozuma K1, Yamaguchi T2, Fujita K3, Yuzawa M3, Suzukamo Y4, Takahashi N5, Takahashi K6, Morita S7, Fukuhara S8 |
|
1Ritsumeikan University, Kusatsu, Japan, 2University of Tokyo, Tokyo, Japan, 3Surugadai Nihon University Hospital, Tokyo, Japan, 4Tohoku University, Sendai, Japan, 5Japan Council for Quality Health Care, Tokyo, Japan, 6Kansai Medical University Hirakata Hospital, Hirakata, Japan, 7Yokohama City University Medical Center, Yokohama, Japan, 8Kyoto University, Kyoto, Japan |
| |
|
| PSS41 |
USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS |
|
Lebwohl M1,
Schenkel B2, Han C3, Yeilding N4, Wang Y4, Papp KA5, Krueger GG6 |
|
1Mount Sinai School of Medicine, New York, NY, USA, 2Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5Probity Medical Research, Waterloo, ON, Canada, 6University of Utah Health Sciences Center, Salt Lake City, UT, USA |
| |
|
| PSS42 |
PSORIASIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE |
|
Boussetta S1, Taieb C2 |
|
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE, France |
| |
|
| PSS43 |
ATOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE |
|
Boussetta S1, Taieb C2 |
|
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE, France |
| |
|
| PSS44 |
ATOPIC DERMATITIS & PSORIASIS: CROSS-EVALUATION OF QUALITY OF LIFE |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS45 |
ATOPICAL DERMATITIS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE |
|
Boussetta S1, Taieb C2 |
|
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE, France |
| |
|
| PSS46 |
MELANOTIC TUMOURS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE |
|
Boussetta S1, Taieb C2 |
|
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE, France |
| |
|
| PSS47 |
ATOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION IN CHILDREN UNDER 15 |
|
Boussetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS48 |
HOSPITAL DERMATOLOGY CONSULTATION TYPES: A FRENCH ASSESSMENT |
|
Bousetta S, Taieb C |
|
Pierre Fabre, Boulogne, France |
| |
|
| PSS49 |
A DISEASE MODEL ILLUSTRATING THE IMPACT OF PSORIASIS ON PATIENTS' LIVES |
|
Marant C1, Emery MP2, Dias-Barbosa C1, Swensen A3, Staniek V2,
Arnould B1 |
|
1Mapi Values France, Lyon, France, 2Mapi Research Trust, Lyon, France, 3Novartis Pharmaceuticals Corp, East Hanover, NJ, USA |
| |
|
| PSS50 |
DEVELOPMENT OF AN INSTRUMENT FOR ASSESSING HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA |
|
Garcia A1, Ortiz de Frutos J2, Peyri J3, Serra E4, Rosales M5, Sabater FJ6,
Badia XB7 |
|
1Hospital de La Princesa, Madrid, Spain, 2Hospital 12 de octubre, Madrid, Spain, 3Hospital Universitari de Bellvitge, L'Hospitalet Llobregat, Barcelona, Spain, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Schering-Plough S.A, Alcobendas, Madrid, Spain, 6Schering-Plough S.A, Alcobendas, Spain, 7IMS Health, Barcelona, Spain |
| |
|
| PSS51 |
SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS) |
|
Meunier J1,
Berdeaux G2, Arnould B1, Viala-Danten M3 |
|
1Mapi Values, Lyon, France, 2Alcon France, Rueil-Malmaison, France, 3Mapi Values France, Lyon, France |
| |
|
| PSS52 |
SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ) |
|
Regnault A1, Vigneux M2, Viala M1,
Berdeaux G3 |
|
1Mapi Values France, Lyon, France, 2Mapi Values, Lyon, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
| PSS53 |
ATOPIC DERMATITIS IN PAEDIATRIC PATIENTS: COMMON CAREGIVER BEHAVIOUR WHEN FACING THE DIFFERENT DISEASE PRESENTATIONS OR LESION SEVERITY. ELIBROT STUDY |
|
Lahoz R1, Torrelo A2, Febrer I3, Lleonart M1 |
|
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Niño Jesús, Madrid, Spain, 3Hospital General Universitario de Valencia, Valencia, Spain |
| |
|
| PSS54 |
EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS: A PATIENT SURVEY ACROSS NINE EUROPEAN COUNTRIES |
|
Conway P1, Dixon S2, Currie CJ3 |
|
1Wyeth Europa, Berkshire, United Kingdom, 2University of Sheffield, Sheffield, United Kingdom, 3Cardiff University, Cardiff, United Kingdom |
| |
|
| PSS55 |
USTEKINUMAB REDUCES WORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS |
|
Reich K1,
Schenkel B2, Han C2, Szapary P3, Li S3, Lebwohl M4, Langley R5 |
|
1Dermatologikum Hamburg, Hamburg, Germany, 2Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Centocor Research and Development, Inc, Malvern, PA, USA, 4Mount Sinai School of Medicine, New York, NY, USA, 5Dalhousie University, Halifax, NS, Canada |
| SENSORY SYSTEMS DISORDERSHealth Care Use & Policy Studies |
| PSS56 |
PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA |
|
Jayawant SS1, Feldman SR2,
Balkrishnan R3 |
|
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA, 3The Ohio State University, Columbus, OH, USA |
| |
|
| PSS57 |
RETROSPECTIVE CHART REVIEW TO ASSESS IMPLEMENTATION OF NICE GUIDANCE ON THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS |
|
Chauhan D1, Drakard M2, Velangi S3, Ralston SJ1 |
|
1Merck Serono, Feltham, United Kingdom, 2Interface Clinical Services, Burley in Wharfdale, United Kingdom, 3City Hospital, Birmingham, United Kingdom |
| |
|
| PSS58 |
A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION. A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN NORTH GERMANY |
|
Augustin M1, Grams L1, Herberger K1, Franzke N1, Debus S2, Rustenbach SJ1 |
|
1University Clinics of Hamburg, Hamburg, Germany, 2Asklepios Klinik Harburg, Hamburg, Germany |
| |
|
| PSS59 |
IMPACT OF HEALTH CARE REGULATION ON PROSTAGLANDIN ANALOGUE PRESCRIBING IN 5 EUROPEAN COUNTRIES |
|
De Natale R1,
Berdeaux G2 |
|
1Padova Hospital, Padova, Italy, 2Alcon France, Rueil-Malmaison, France |
| SENSORY SYSTEMS DISORDERSConceptual Papers & Research on Methods |
| PSS60 |
DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL |
|
Lebwohl M1,
Schenkel B2, Han C2, Papp KA3, Krueger GG4 |
|
1Mount Sinai School of Medicine, New York, NY, USA, 2Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA, USA, 3Probity Medical Research, Waterloo, ON, Canada, 4University of Utah Health Sciences Center, Salt Lake City, UT, USA |
| |
|
SYSTEMIC DISORDERS/CONDITIONSClinical Outcomes Studies
| PSY1 |
A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) IN THE ON-DEMAND TREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBITORS |
|
Knight C1, Dano AM2, Kennedy-Martin T3 |
|
1RTI Health Solutions, Manchester, United Kingdom, 2Novo Nordisk A/S, Virum, Denmark, 3KMHO, Brighton, United Kingdom |
| |
|
| PSY2 |
CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE |
|
Clarke J1, Beck M2, Giugliani R3, Sunder-Plassmann G4, Elliott P5, Hernberg-Stahl E6, Mehta A7 |
|
1Hospital for Sick Children, Toronto, Ontario, Canada, 2University of Mainz, Mainz, Germany, 3Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, 4Medical University Vienna, Vienna, Austria, 5Heart Hospital, London, United Kingdom, 6Shire HGT, Danderyd, Sweden, 7Royal Free Hospital, London, United Kingdom |
| |
|
| PSY3 |
PREVALENCE OF METABOLIC ABNORMALITIES AMONG OBESE ADULTS IN KOREA. |
|
Lee SY1, Kim SJ1, Kim Y-K2, Choi Y3, Jung SH4 |
|
1Ajou University College of Medicine, Suwon, South Korea, 2Kyunghee University, Seoul, South Korea, 3sanofi-aventis Korea, Seoul, South Korea, 4Ehwa Womans University, Seoul, South Korea |
| |
|
| PSY4 |
EPIDEMIOLOGY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS |
|
Gerlier L1, De Vos C1, Lamotte M1, Malfait M2, Poitrinal P3 |
|
1IMS Health, Brussels, Belgium, 2Amgen NV, Brussels, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland |
| |
|
| PSY5 |
FACTORS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY |
|
Thaipanich A, Wongchinsri J, Hemachudha A, Auamnoy T |
|
Chulalongkorn University, Bangkok, Thailand |
| |
|
| PSY6 |
PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12-17 |
|
Sias S1, Hufstader MA1, White-Means SI2, Gourley D1, Vaidya V2 |
|
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, Memphis, TN, USA |
| SYSTEMIC DISORDERS/CONDITIONSCost Studies |
| PSY7 |
THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION |
|
Campbell J1, McGarry LJ1, Gilmore K1,
Hale B2, Weinstein MC3, Shikora S4 |
|
1i3 Innovus, Medford, MA, USA, 2Allergan Pharmaceuticals, Irvine, CA, USA, 3Harvard University, Boston, MA, USA, 4Tufts-New England Medical Center, Boston, MA, USA |
| |
|
| PSY8 |
BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETA THALASSAEMIA IN VENETO REGION, ITALY |
|
Venturini F,
Adami S, Alberti C, Scroccaro G |
|
Veneto Regional Drug Information Center, Verona, Italy |
| |
|
| PSY9 |
BUDGET IMPACT OF THE USE OF OROS® HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM |
|
Fleischmann J1, Bergman G2, Verkuijlen G3, Lam A4 |
|
1Janssen-Cilag GmbH, Neuss, Germany, 2Mapi Values, Houten, Netherlands, 3Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA, 4Johnson & Johnson Pharmaceutical Services, Toronto, ON, Canada |
| |
|
| PSY10 |
ESTIMATION OF THE COSTS FOR A HEREDITARY HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME PER 100.000 INDIVIDUALS UNDER 30 YEARS OF AGE IN SPAIN |
|
Saz-Parkinson Z1, Amate JM1, Ayuso C2 |
|
1Instituto de Salud Carlos III, Madrid, Spain, 2Fundación Jiménez Díaz, Madrid, Spain |
| |
|
| PSY11 |
EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN THE UK |
|
Webber JM1, Lloyd AC1,
Lebmeier M2, Conway P3, Warburton J2 |
|
1IMS Health, London, United Kingdom, 2Wyeth Pharmaceuticals, Maidenhead, United Kingdom, 3Wyeth Europa, Berkshire, United Kingdom |
| |
|
| PSY12 |
COST-EFFECTIVENESS OF FOOD FOR SPECIAL MEDICAL PURPOSES RELATIVE TO STANDARD CARE IN PATIENTS UNDERGOING ABDOMINAL SURGERY |
|
Nuijten MJ1, Freyer K2, Ceri Green J3 |
|
1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, Netherlands, 2Nutricia Advanced Medical Nutrition, Zoetermeer, Netherlands, 3Danone Medical Nutrition, Schiphol, Netherlands |
| |
|
| PSY13 |
WITHDRAWN |
|
|
|
|
| |
|
| PSY14 |
COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV: TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER INSTITUTE (MEX-INCAN) |
|
Cervera-Ceballos E1, Meneses A1,
Vargas J2 |
|
1National Institute of Cancer, México, DF, Mexico, 2Econopharma Consulting SA de CV, Mexico, DF, Mexico |
| |
|
| PSY15 |
ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME |
|
Migliaccio-Walle K1, Baladi JF2 |
|
1United BioSource Corporation, Concord, MA, USA, 2Novartis Pharmaceuticals Corp, Florham Park, NJ, USA |
| |
|
| PSY16 |
THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS: THE CASE OF USING ACTIVATED RECOMBINANT FACTOR VII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS |
|
Odeyemi IA1, Dano AM2 |
|
1Novo Nordisk A/S, Pinner, United Kingdom, 2Novo Nordisk A/S, Virum, Denmark |
| |
|
| PSY17 |
PRECISE STUDY: BASELINE ANALYSIS OF A COST EFFECTIVENESS STUDY ON FAILED BACK SURGERY SYNDROME |
|
Beccagutti G1, Zucco F2, Lavano A3, De Rose M3, Poli P4, Fortini G5, De Martini L6, De Simone E7, Menardo V8, Cisotto P9, Meglio M10, Costantini A11 |
|
1Medtronic Italy, Sesto San Giovanni, Italy, 2Azienda Ospedaliera, Garbagnate Milanese, Milano, Italy, 3Campus Universitario di Germaneto, Catanzaro, Italy, 4Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 5Ospedale di Circolo e Fondazione Macchi, Varese, Italy, 6Fondazione Maugeri, Pavia, Italy, 7Ospedale Maffucci, Avellino, Italy, 8Ospedale S. Croce e Carle, Cuneo, Italy, 9Ospedale Regionale S. M. dei Battuti, Treviso, Italy, 10Azienda Universitaria Policlinico A. Gemell, Roma, Italy, 11Policlinico SS Annunziata, Chieti, Italy |
| |
|
| PSY18 |
COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT: A FINNISH HOSPITAL PERSPECTIVE ANALYSIS |
|
Van den Steen D1, Van Bellinghen LA1, Liwing J2, Van Vlaenderen I1, Lamotte M1, Lothgren M2, Annemans L3 |
|
1IMS Health, Brussels, Belgium, 2Janssen-Cilag AB, Sollentuna, Sweden, 3University of Ghent, Brussels University, Ghent, Belgium |
| |
|
| PSY19 |
MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTH TECHNOLOGY ASSESSMENT |
|
Vauth C1, Stöber Y1, Bockelbrink A2, Greiner W3 |
|
1Leibniz University Hannover, Hannover, Germany, 2Charité University Medical Center, Berlin, Germany, 3University of Bielefeld, Bielefeld, Germany |
| |
|
| PSY20 |
WITHDRAWN |
|
|
|
|
| |
|
| PSY21 |
COST-MINIMIZATION ANALYSIS OF ORAL VS. INTRAVENOUS FLUDARABINE (BENEFLUR®) IN SPAIN |
|
Delgado J1,
Febrer L2, Nieves D3, Piñol C2, Brosa M3 |
|
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Bayer HealthCare, Barcelona, Spain, 3Oblikue Consulting, Barcelona, Spain |
| |
|
| PSY22 |
PROCESS STUDY: A 6-MONTHS COST-CONSEQUENCE ANALYSIS IN CHRONIC PAIN FROM THE SPANISH PERSPECTIVE |
|
Molet J1, Solivera J1, Rodriguez JM2,
González P2, Baena M2 |
|
1Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 2Medtronic Iberia, Madrid, Spain |
| |
|
| PSY23 |
WITHDRAWN |
|
|
|
|
| |
|
| PSY24 |
MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM: A COST OF ILLNESS STUDY |
|
Caekelbergh K1, Lamotte M1, Muchada JP2 |
|
1IMS Health, Brussels, Belgium, 2Sanofi Pasteur MSD, Brussels, Belgium |
| |
|
| PSY25 |
SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF SYSTEMIC LUPUS ERYTHEMATOSUS |
|
Richard L, Brown M,
Tan SC
|
|
UCB
Celltech, Slough, United Kingdom |
| |
|
| PSY26 |
COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006 |
|
Chrzanowski M1,
Czech M1, Hermanowski T1, Sykut-Cegielska J2 |
|
1Medical University of Warsaw, Warsaw, Poland, 2Children's Memorial Health Institute, Warsaw, Poland |
| |
|
| PSY27 |
HEALTHCARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS |
|
Morera Domínguez C1, Ceberio Balda F2, Flórez García M3, Masramón X4, Freire O5,
Rejas J5 |
|
1Hospital Mutua de Terrasa, Barcelona, Spain, 2Hospital de Urbamin, Pamplona, Spain, 3Foundation Hospital Alcorcón, Madrid, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
| PSY28 |
HEALTH CARE AND NON-HEALTHCARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS |
|
Rejas J1, Morera Domínguez C2, Ceberio Balda F3, Flórez García M4, Masramón X5, Freire O1 |
|
1Pfizer Spain, Madrid, Spain, 2Hospital Mutua de Terrasa, Barcelona, Spain, 3Hospital de Urbamin, Pamplona, Spain, 4Foundation Hospital Alcorcón, Madrid, Spain, 5European Biometrics Institute, Barcelona, Spain |
| |
|
| PSY29 |
TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE |
|
Ehlken B1, Berger K1, Leithäuser M2, Koester U3, Schmid C4, Thalheimer M5, Plesnila-Frank C1, Freund M2, Junghanss C2 |
|
1IMS Health, Munich, Germany, 2University Hospital Rostock, Rostock, Germany, 3Asklepios proresearch, Hamburg, Germany, 4Hospital Augsburg, Augsburg, Germany, 5University Hospital Heidelberg, Heidelberg, Germany |
| |
|
| PSY30 |
HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY: IS INITIAL DOSING A SIGNIFICANT FACTOR? |
|
Zhao Y1, Boulanger L2, Wu N2, Lamothe K2, Russell MW2 |
|
1Eli Lilly and Company, Indianapolis, IN, USA, 2Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA |
| |
|
| PSY31 |
ECONOMIC IMPACT OF THE FABRY-ANDERSON DISEASE TREATMENT |
|
De Portu S, Pisani A, Scalzone A, Cianciaruso B, Mantovani LG |
|
University Federico II, Naples, Italy |
| |
|
| PSY32 |
COSTS OF A BLOOD TRANSFUSION IN HEMATO-ONCOLOGIC PATIENTS IN A PORTUGUESE HOSPITAL |
|
Brilhante D1, Macedo A2, Santos A2,
Pereira C3 |
|
1Instituto Português de Oncologia de Lisboa,
Francisco Gentil, EPE, Lisbon, Portugal, 2KeyPoint,
Consultoria Científica Lda, Lisbon, Portugal, 3Roche
Farmacêutica Química, Lda, Amadora, Portugal |
| |
|
| PSY33 |
CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLOOD TRANSFUSION DURING INPATIENT HOSPITALIZATION: AN ANALYSIS OF THE 2004 HEALTH CARE COST AND UTILIZATION PROJECT NATIONWIDE INPATIENT SAMPLE DATABASE |
|
Patel ST1,
Anastassopoulos K1, Lerner J1, Ryan K1, Dodd SL2, Goss TF1, Morton J3 |
|
1Covance Market Access Services, Gaithersburg, MD, USA, 2Ethicon, Inc, Silesia, MT, USA, 3Stanford University School of Medicine, Stanford, CA, USA |
| |
|
| PSY34 |
COSTS AND PATIENT-REPORTED OUTCOMES (PRO) IN GERMAN PATIENTS WITH CHRONIC KNEE AND HIP PAIN |
|
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1 |
|
1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
| PSY35 |
COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY RESULTS (ONVIDA GROUP) |
|
Camps C1, Casas A2, Barón F3, Colmenarejo A4, Jara C5, Lobo F6, Massuti B7, Poveda JL8, Rifá J9,
Rubio-Terrés C10 |
|
1Hospital General Universitario de Valencia, Valencia, Spain, 2Hospital Universitario Virgen del Rocio, Seville, Spain, 3Hospital Universitario Santiago de Compostela, Santiago de Compostela, La Coruña, Spain, 4Hospital Central de la Defensa, Madrid, Spain, 5Hospital Unversitario de Alcorcón, Alcorcón, Madrid, Spain, 6Hospital Fundcaión Jiménez Díaz, Madrid, Spain, 7Hospital General de Alicante, Alicante, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital Son Dureta, Palma de Mallorca, Balearic Islands, Spain, 10Health Value, Madrid, Spain |
| |
|
| PSY36 |
EUROPEAN ECONOMIC EVALUATION OF OROS® HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN |
|
Hauber AB1,
Lam A2, Fleischmann J3, Wilson MR1 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson Pharmaceutical Services, Toronto, ON, Canada, 3Janssen-Cilag GmbH, Neuss, Germany |
| |
|
| PSY37 |
HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII |
|
Asukai Y1, Lloyd AC1, Ghatnekar O2,
Hutchings AS3 |
|
1IMS Health, London, United Kingdom, 2The Swedish Institute for Health Economics, Lund, Sweden, 3Baxter Healthcare, Newbury, Berkshire, United Kingdom |
| |
|
| PSY38 |
IMPACT OF TENSION HEADACHE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT |
|
Bolge SC, Kannan H, Wagner S |
|
Consumer Health Sciences, Princeton, NJ, USA |
| |
|
| PSY39 |
IMPACT OF HIGH WAIST CIRCUMFERENCE ON PRODUCTIVITY IN US AND GERMAN OVERWEIGHT/OBESE SUBJECTS |
|
Caterson I1, Hauner H2, Amand C3, Sherrill B4, Wolf A5 |
|
1University of Sydney, Camperdown, Australia, 2Klinik Für ErnährungsmedizinKlinikum Rechts der, München, Germany, 3Sanofi-Aventis, Paris, France, 4RTI Health Solutions, Research Triangle Park, NC, USA, 5University of Virginia, Charlottesville, VA, USA |
| |
|
| PSY40 |
BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS) |
|
Lister S |
|
Pfizer Limited, Tadworth, Surrey, United Kingdom |
| |
|
| PSY41 |
REVIEW OF HOME READINESS INSTRUMENTS TO ASSESS RECOVERY POST-SURGERY |
|
Asmussen M1, Wendicke K1, Heyes A2, Priaulx J2, Goad C2 |
|
1Nycomed, Roskilde, Denmark, 2Mapi Values, Macclesfield, United Kingdom |
| SYSTEMIC DISORDERS/CONDITIONSPatient-Reported Outcomes Studies |
| PSY42 |
E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES |
|
Marino B, Platko J, Raymond S |
|
PHT Corporation, Boston, MA, USA |
| |
|
| PSY43 |
THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D) |
|
Sanz M1, Aledort L2, Danese M3, Guo M4, Isitt J4 |
|
1University Hospital La Fe, Valencia, Spain, 2Mount Sinai Hospital, New York, NY, USA, 3Outcomes Insights, Inc, Newbury Park, CA, USA, 4Amgen, Thousand Oaks, CA, USA |
| |
|
| PSY44 |
UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUES |
|
Brod M1, Hammer M2, Lessard S3, Kragh N2 |
|
1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3The Brod Group, Mill Valley, CA, USA |
| |
|
| PSY45 |
PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS |
|
Molta CT, Boggs R, Singh A, Yang S |
|
Wyeth Pharmaceuticals, Inc, Collegeville, PA, USA |
| |
|
| PSY46 |
PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF MIGRAINE IN GERMANY |
|
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1 |
|
1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
| PSY47 |
PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS. |
|
Flórez García M1, Morera Domínguez C2, Ceberio Balda F3, Masramón X4, Freire O5,
Rejas J5 |
|
1Foundation Hospital Alcorcón, Madrid, Spain, 2Hospital Mutua de Terrasa, Barcelona, Spain, 3Hospital de Urbamin, Pamplona, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
| PSY48 |
EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA: PATIENT-REPORTED DATA. INTERMEDIATE RESULTS. PART 2 |
|
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4, Telnova E5, Tonoyan A2 |
|
1Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, 2Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow, Russia, 4Hematological Research Center, Moscow, Russia, 5Roszdravnadzor, Moscow, Russia |
| |
|
| PSY49 |
PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN: A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL PRACTICE. |
|
Pérez C1, Navarro A2, Saldaña MT3, Masramón X4,
Rejas J5 |
|
1Hospital University La Princesa, Madrid, Spain, 2Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 3Primary Care Centre “Raíces”, Castrillón, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
| PSY50 |
ASSESSING THE VALUE OF 24-HOUR CHRONIC PAIN CONTROL FROM THE PATIENT PERSPECTIVE: DO EXISTING PATIENT-REPORTED OUTCOMES INSTRUMENTS ADEQUATELY COVER THE RELEVANT CONCEPTS RELATED TO 24-HOUR CHRONIC PAIN CONTROL? |
|
Guillemin I1,
Lam A2, Richarz U3, Kavanagh S4, Emery MP5, Benmedjahed K1, Dubois D4, Arnould B1 |
|
1Mapi Values, Lyon, France, 2Johnson & Johnson Pharmaceutical Services, Toronto, ON, Canada, 3Johnson & Johnson Pharmaceutical Services, Baar, Switzerland, 4Johnson & Johnson Pharmaceutical Services, Beerse, Belgium, 5Mapi Research Trust, Lyon, France |
| |
|
| PSY51 |
PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS |
|
Ceberio Balda F1, Flórez García M2, Morera Domínguez C3, Masramón X4, Freire O5,
Rejas J5 |
|
1Hospital de Urbamin, Pamplona, Spain, 2Foundation Hospital Alcorcón, Madrid, Spain, 3Hospital Mutua de Terrasa, Barcelona, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
| PSY52 |
QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES. INTERMEDIATE RESULTS |
|
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4, Telnova E5, Tonoyan A2 |
|
1Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia, 2Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow, Russia, 4Hematological Research Center, Moscow, Russia, 5Roszdravnadzor, Moscow, Russia |
| |
|
| PSY53 |
SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD |
|
Rofail D1, Abetz L1, Heelis R1, Baladi JF2 |
|
1Mapi Values, Bollington, Cheshire, United Kingdom, 2Novartis Pharmaceuticals Corp, Florham Park, NJ, USA |
| |
|
| PSY54 |
UNDERSTANDING PATIENT PERCEPTION OF THE BIOENTERICS INTRAGASTRIC SYSTEM FOR WEIGHT REDUCTION |
|
Hale B1, Stern L2, Ogbonnaya A2, Walt JG1, Buchholz P3 |
|
1Allergan Pharmaceuticals, Irvine, CA, USA, 2Analytica International, New York, NY, USA, 3Allergan Ettlingen, Ettlingen, Germany |
| |
|
| PSY55 |
PAIN MANAGEMENT IN THAILAND: IMPLICATION FOR BETTER PATIENT EDUCATION |
|
Layton MR1, Chadbunchachai S1, Kerr SJ2 |
|
1Khon Kaen University, Khon Kaen, Thailand, 2University of New South Wales, Sydney, Australia |
| |
|
| PSY56 |
HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS |
|
Brown TM1, Lee WC2, Joshi AV3, Pashos CL1 |
|
1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Abt Bio-Pharma Solutions, Inc, Bethesda, MD, USA, 3Novo Nordisk Inc, Princeton, NJ, USA |
| SYSTEMIC DISORDERS/CONDITIONSHealth Care Use & Policy Studies |
| PSY57 |
USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS ECONOMIC BURDEN IN FRANCE |
|
Vainchtock A1, Bogillot O2, Divine M2, Durand-Zaleski IS3 |
|
1HEVA, Lyon, France, 2Amgen France, Neuilly-Sur-Seine, France, 3APHP Henri Mondor hospital, Créteil, France |
| |
|
| PSY58 |
RETROSPECTIVE ANALYSIS OF FACTOR VIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII |
|
Epstein JD1, Woo P1, Hutchings AS2, Li-McLeod J1 |
|
1Baxter BioScience, Westlake Village, CA, USA, 2Baxter Healthcare, Newbury, Berkshire, United Kingdom |
| |
|
| PSY59 |
A POPULATION STUDY ON THE AGE-SPECIFIC RELATIONSHIP BETWEEN BODY MASS INDEX, METABOLIC DISORDERS, AND UTILIZATION OF AMBULATORY SERVICES |
|
Chang HY1, Liu WL1, Chu NF2, Hsiao CF1 |
|
1National Health Research Institutes, Zhunan, Maoli, Taiwan, 2National Defense Medical Center, Taipei, Taiwan |
| |
|
| PSY60 |
PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12-17 YEARS OF AGE |
|
Sias S1, Hufstader MA1, White-Means S1, Gourley D1, Vaidya V2 |
|
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, Memphis, TN, USA |
| |
|
| PSY61 |
INCREMENTAL SAVINGS ASSOCIATED WITH A DECREASE IN ANTIDEPRESSANT MEDICATIONS FOLLOWING BARIATRIC SURGERY IN WESTERN NEW YORK |
|
Purdy CH1,
Hayward A1, Magar RS2, Iskedjian M3 |
|
1PharmIdeas Research and Consulting, Buffalo, NY, USA, 2PharmIdeas Research and Consulting, Raleigh, NC, USA, 3PharmIdeas Research and Consulting, Oakville, ON, Canada |
| |
|
| PSY62 |
A NATURAL EXPERIMENT TO ESTIMATE THE IMPACT OF A PREFERRED DRUG LIST POLICY FOR LONG ACTING NARCOTIC ANALGESICS ON COSTS AND UTILIZATION |
|
Flannagin KR, Martin BC |
|
University of Arkansas for Medical Sciences, Little Rock, AR, USA |
| |
|
| PSY63 |
PATIENT-REPORTED OUTCOMES (PRO'S) AND ECONOMICS OF NEUROPATHIC PAIN IN GERMANY |
|
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1 |
|
1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
| PSY64 |
PATIENT-REPORTED OUTCOMES (PRO'S) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY |
|
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1 |
|
1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
URINARY/KIDNEY DISORDERSClinical Outcomes Studies
| PUK1 |
CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION: THE ICEBERG STUDY |
|
Font B1, Saval N1, Gatell S1, Andrés I1, Grinyó JM2, Campistol JM3 |
|
1Novartis Farmacéutica S.A, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, 3Hospital Clínic i Provincial de Barcelona, Barcelona, Spain |
| URINARY/KIDNEY DISORDERSCost Studies |
| PUK2 |
IN GREECE, INCREASING THE UTILIZATION OF PERITONEAL DIALYSIS THERAPY MAY REDUCE OVERALL DIALYSIS EXPENDITURES |
|
Walker DR, Just PM |
|
Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA |
| |
|
| PUK3 |
THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY |
|
Bademlioglu C1, Guloksuz Y1, Hisarli C1, Walker DR2,
Just PM2 |
|
1Baxter Healthcare Corporation, Instanbul, Turkey, 2Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA |
| |
|
| PUK4 |
PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY |
|
Pradelli L, Iannazzo S |
|
AdRes Srl, Turin, Italy |
| |
|
| PUK5 |
COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS |
|
Borghetti F1, Scalone L1, Brancati B1, Sottini L2, Brunori G2, Viola BF2, Cancarini G2, Mantovani LG3 |
|
1Centre of Pharmacoeconomics, University of Milan, Milan, Italy, 2Spedali Civili, Brescia, Italy, 3University of Naples, Federico II, Naples, Italy |
| |
|
| PUK6 |
COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION (SNM) FOR PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE NETHERLANDS |
|
Van Genugten M1, Leong R2, Brosa M3, Stauble F4 |
|
1Medtronic Trading NL B.V, Heerlen, DA, Netherlands, 2Academic Medical Centre Maastricht, Maastricht, Netherlands, 3Oblikue Consulting, Barcelona, SC, Spain, 4Medtronic International Trading Sarl, Tolochenaz, Switzerland |
| |
|
| PUK7 |
A TEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS OF THE SPANISH INTEGRATED RENAL REPLACEMENT THERAPY PROGRAM |
|
Villa G1, Cuervo J1, Ortiz LF1, Sánchez JE2, Rebollo P1 |
|
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain |
| |
|
| PUK8 |
FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF AN ECONOMIC MODEL |
|
Kelleher C1, Snedecor SJ2, Botteman MF2, Lee R3, Najib H4, Weinstein D5, Trocio J6 |
|
1St. Thomas' Hospital, London, United Kingdom, 2Pharmerit North America, LLC, Bethesda, MD, USA, 3Weill Medical College of Cornell University, New York, NY, USA, 4Pfizer Ltd, Surrey, United Kingdom, 5Pfizer France, Paris, France, 6Pfizer Inc, New York, NY, USA |
| |
|
| PUK9 |
COST OF OVERACTIVE BLADDER IN THE UNITED STATES |
|
Ganz ML1, Smalarz AM1, Anger JT2, Krupski TL3, Hu JC4, Wittrup-Jensen KU5, Pashos CL1 |
|
1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2David Geffen School of Medicine, UCLA, Los Angeles, CA, USA, 3Duke Medical Center, Raleigh, NC, USA, 4Brigham and Women's Hospital, Boston, MA, USA, 5Bayer Schering Pharma AG, Berlin, Germany |
| |
|
| PUK10 |
ECONOMIC IMPACT OF A LOW-PROTEIN DIET AIMING TO DELAY THE HAEMODIALYSIS TREATMENT IN PATIENTS WITH CHRONIC-RENAL-FAILURE |
|
de Portu S1, Cianciaruso B2, Pota A2, di Miccio L2, Di Palma A1, Pisani A2, Mantovani LG1 |
|
1Faculty of Pharmacy, University Federico II, Naples, Italy, 2School of Medicine, University Federico II, Naples, Italy |
| |
|
| PUK11 |
A COST-UTILITY ANALYSIS OF SOLIFENACIN 5MG AND SOLIFENACIN 10MG VERSUS TOLTERODINE ER 4MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) |
|
Cardozo L1, Thorpe A2, Grishchenko M3,
Sidhu MK4 |
|
1Kings College Hospital, London, United Kingdom, 2Freeman Hospital, Newcastle, United Kingdom, 3Abacus International, Bicester, United Kingdom, 4Astellas Pharma Europe Ltd, Staines, United Kingdom |
| |
|
| PUK12 |
A COST-UTILITY ANALYSIS OF SOLIFENACIN 5MG AND 10MG VERSUS FESOTERODINE 4MG AND 8MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS |
|
Cardozo L1, Thorpe A2, Grishchenko M3,
Sidhu MK4 |
|
1Kings College Hospital, London, United Kingdom, 2Freeman Hospital, Newcastle, Tyne and Wear, United Kingdom, 3Abacus International, Bicester, Oxon, United Kingdom, 4Astellas Pharma Europe Ltd, Staines, Middlesex, United Kingdom |
| |
|
| PUK13 |
EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION: RESULTS OF ECONOMIC EVALUATION |
|
Ortega T, Ortega F, Baltar JM, Valdés C, Diaz-Corte C, Gómez E |
|
Hospital Universitario Central de Asturias, Oviedo, Spain |
| |
|
| PUK14 |
A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH HAEMODIALYSIS |
|
Van Bellinghen LA1, Lamotte M2, Malfait M3 |
|
1IMS HEOR, Brussels, Belgium, 2IMS Health, Brussels, Belgium, 3Amgen NV, Brussels, Belgium |
| |
|
| PUK15 |
ASSESSMENT OF THE BENEFITS OF TIME SAVINGS ACHIEVED BY ONCE MONTHLY INJECTION OF ERYTHROPOIETIN STIMULATING AGENTS (ESA) ON ANAEMIA MANAGEMENT IN HAEMODIALYSIS CENTRES |
|
Allard B1, Grégoire M2, Ferrandini C3, Ollivier C4, Vrtovsnik F5, Zambrowski JJ6, Lamure E7,
Baillon N8 |
|
1ECHO de Nantes, Rezé, France, 2AURA Paris, Paris, France, 3CRAT, Tassin La Demi Lune, France, 4CHR Caen, Caen, France, 5CH Bichat, Paris, France, 6Université René Descartes - Paris V, Paris, France, 7IMS Health, Puteaux, France, 8Roche, Neuilly, France |
| URINARY/KIDNEY DISORDERSPatient Reported Outcomes |
| PUK16 |
EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES |
|
Hollingworth W1, Campbell JD2, Kowalski J3, Ravelo A3,
Girod I4, Briggs A5, Sullivan SD2 |
|
1University of Bristol, Bristol, United Kingdom, 2University of Washington, Seattle, WA, USA, 3Allergan, Inc, Irvine, CA, USA, 4Allergan Limited, Marlow, United Kingdom, 5University of Glasgow, Glasgow, United Kingdom |
| |
|
| PUK17 |
ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER |
|
Verheggen BG1, Treur MJ1, Heeg BMS1, Botteman MF2, Van Hout BA1, Trocio JN3 |
|
1Pharmerit Europe, Rotterdam, Netherlands, 2PharMerit North America LLC, Bethesda, MD, USA, 3Pfizer Inc, New York, NY, USA |
| |
|
| PUK18 |
VALIDATION OF THE URINARY SENSATION SCALE (USS) |
|
Coyne KS1, Margolis MK1, Jumadilova Z2,
Vats V2, Hsieh R1 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer Inc, New York, NY, USA |
| |
|
| PUK19 |
PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES |
|
Coyne KS1, Margolis MK1,
Weinstein D2, Ebel-Bitoun C2 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer France, Paris, France |
| |
|
| PUK20 |
VALIDATION OF THE SPANISH VERSION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL QUESTIONNAIRE-SHORT FORM (PISQ-12) |
|
Rebollo P1, Espuña PM2, Puig-Clota M2, Gonzalez A2, Zardain PC1 |
|
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Institut Clínic de Ginecología Obstetricia i Neonatología. Hospital Clínic. Universidad de Barcelona, Barcelona, Spain |
| |
|
| PUK21 |
CONTENT VALIDITY OF THE SUBJECT'S ASSESSMENT OF CONDITION, SUBJECT'S ASSESSMENT OF TREATMENT SATISFACTION, KING'S HEALTH QUESTIONNAIRE, AND INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE – SHORT FORM IN PATIENTS WITH OAB |
|
Margolis MK1, Coyne KS1,
Vats V2 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA |
| |
|
| PUK22 |
FACTORS ASSOCIATED WITH PERCEIVED SATISFACTION IN HEMODYALISIS PATIENTS |
|
Valdes C1, Miguel M1, Artos Y1, Alvarez M2, Portero E2, Ortega T1, Ortega F1 |
|
1Hospital Universitario Central de Asturias, Oviedo, Spain, 2Cruz Roja de Oviedo, Oviedo, Spain |
| URINARY/KIDNEY DISORDERSHealth Care Use & Policy Studies |
| PUK23 |
WITHDRAWN |
|
|
|
|
11th Annual European Congress Main Page
|
|